(Total Views: 585)
Posted On: 02/08/2020 1:09:07 PM
Post# of 30067
AMBS currently owns 80.01% of Breakthrough Diagnostics, Inc., which is a joint venture with Todos Medical, Ltd. AMBS licensed the intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test as well as certain rights to the multiple sclerosis diagnostic MSPrecise™ and the Parkinson’s diagnostic NuroPro to Breakthrough.
Todos has exercised its exclusive option to acquire Amarantus’ remaining 80.01% ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the first half of 2020.
After the closing, AMBS will own almost half of Todos and Todos will own 100% of Breakthrough.
Todos has exercised its exclusive option to acquire Amarantus’ remaining 80.01% ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the first half of 2020.
After the closing, AMBS will own almost half of Todos and Todos will own 100% of Breakthrough.
(1)
(0)
